Olaparib for HRD malignant mesothelioma after platinum chemotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether olaparib (a cancer medicine) can help control malignant mesothelioma that has specific DNA changes. You must have already had platinum chemotherapy and your cancer must be “platinum-sensitive,” plus your tumor (or family/genetic cells) must show certain gene problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed malignant mesothelioma diagnosed by a physician and you’re 18 or older
- You must be willing to sign consent before any study tests and agree to genetic testing of both tumor and normal cells
- Your mesothelioma must have specific DNA findings, such as BAP1 loss or a gene change that disrupts protein function
- You must have had cisplatin or carboplatin before, and your cancer must not have grown during treatment or for at least 3 months after
- Your blood counts and organ function must be adequate on recent lab tests, and you must be well enough for daily activities (ECOG 0–1)
- Your tumor must be measurable on CT scans and have at least one untargeted lesion that meets size limits; you must not have certain serious health exclusions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.